He is also one of the founders and authorities of the international clinical research on targeted therapy of lung cancer. He has published more than 160 peer-reviewed papers in prestigious journals such as The New England Journal of Medicine, The Lancet Oncology, And Nature. Dr. Drilon has served as a principal investigator in a number of clinical trials, including the recent Phase I/II trial of a RET selective inhibitor, Selpercatinib, which has been conditionally approved for marketing by the FDA. In addition, Dr. Drilon said in an interview after the WCLC2019 conference, “one of the issues we cannot ignore is what happens after acquired resistance to RET selective inhibitors? At present, there are also some new drug companies accelerating the development of the second generation of RET fusion gene mutation-targeting drugs, hoping to overcome the problem of acquired resistance to RET selective inhibitors in the near future ”. Based on the expectation of the new generation of selective inhibitors, we are honored to invite Dr. Alexander Drilon as a member of the Scientific Advisory Board of APS. His clinical experience and profound insights in professional fields will help APS develop new generations of precision oncology therapies to benefit cancer patients around the world as soon as possible.